Insider Buy: Harvard Bioscience
4:32PM ET 6/17/2022 MT NewswiresJames W Green, Director, Chief Executive Officer, on June 15, 2022, executed a purchase for 30,000 shares in Harvard Bioscience (HBIO) for $111,300....
Quotes Snapshot > HBIO
Harvard Bioscience Inc HBIO:NASDAQ
Last Price$3.70NASDAQ Previous Close - Last Trade as of 4:00PM ET 7/01/22
Today's Change+0.10(2.78%)
Bid (Size)$1.75 (25)
Ask (Size)$3.82 (2)
Day Low / High$3.59 - 3.75
Volume201.4 K
Read more news Recent News
-- Earnings Flash (HBIO) HARVARD BIOSCIENCE Posts Q1 Revenue $28.8M, vs. Street Est of $28.7M
7:04AM ET 5/04/2022 MT Newswires...
-- Earnings Flash (HBIO) HARVARD BIOSCIENCE Reports Q1 EPS $0.04, vs. Street Est of $0.06
7:04AM ET 5/04/2022 MT Newswires...
-- Earnings Flash (HBIO) HARVARD BIOSCIENCE Posts Q4 EPS $0.08, vs. Street Est of $0.11
7:01AM ET 3/08/2022 MT Newswires...
View all Commentary and Analysis
Harvard Bioscience, Inc. 2022 Q1 - Results - Earnings Call Presentation
3:03AM ET 5/05/2022 Seeking AlphaHarvard Bioscience, Inc. (HBIO) CEO James Green on Q1 2022 Results - Earnings Call Transcript
12:36PM ET 5/04/2022 Seeking AlphaHarvard Bioscience - Dressed Up And Waiting For A Suitor
10:09AM ET 3/15/2022 Seeking AlphaHarvard Bioscience, Inc. (HBIO) CEO James Green on Q4 2021 Results - Earnings Call Transcript
2:07PM ET 3/08/2022 Seeking AlphaCompany Profile
Business DescriptionHarvard Bioscience, Inc. develops, manufactures, and sells technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. It operates under the geographical segments: United States, Germany, United Kingdom, and Rest of the world. It sells its products through catalog, Website, distributors, and direct sales force. The company was founded by Dr. William T. Porter in 1901 and is headquartered in Holliston, MA. View company web site for more details
| Address | 84 October Hill Road Holliston, Massachusetts 01746-1371 |
| Phone | +1.508.893.8999 |
| Number of Employees | 547 |
| Recent SEC Filing | 06/21/2022 SC 13G |
| Chairman, President & Chief Executive Officer | James W. Green |
| Chief Financial Officer | Michael A. Rossi |
| Vice President-Global Sales, Preclinical Systems | Ryan Wallace |
| Chief Marketing Officer | Jacques Coumans |
Company Highlights
| Price Open | $3.61 |
| Previous Close | $3.60 |
| 52 Week Range | $3.25 - 8.75 |
| Market Capitalization | $152.6 M |
| Shares Outstanding | 41.2 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 08/04/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$0.05 |
| Beta vs. S&P 500 | N/A |
| Revenue | $120.8 M |
| Net Profit Margin | -5.38% |
| Return on Equity | -8.24% |
Analyst Ratings as of 05/19/2022
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |